Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib versus sorafenib after TACE failure in intermediate-stage hepatocellular carcinoma
ChiCTR2300072771Phase 3Not yet recruiting
- Sponsor
- Beijing Ditan Hospital
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of lenvatinib and sorafenib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Beijing Ditan Hospital. Primary endpoint: Progression-free survival. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
lenvatinibsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300072771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072771.